Pricing Log in Create free account

Corcept Therapeutics Incorporated (CORT) vs ImmunityBio, Inc. (IBRX)

Corcept Therapeutics Incorporated and ImmunityBio, Inc. are both Biotechnology companies. Corcept Therapeutics Incorporated and ImmunityBio, Inc. are of similar size ($8.5B and $7.8B). ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; Corcept Therapeutics Incorporated trades at 47.8×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 30.0%. Corcept Therapeutics Incorporated has the higher net margin (16.5% vs −598.6%) and the higher return on invested capital (15.0% vs 0.00%). Across the 18 metrics below, Corcept Therapeutics Incorporated leads on 10 and ImmunityBio, Inc. on 8.

Valuation

Metric CORT IBRX Biotechnology median
P/E 47.81 n/m 10.60
P/S 8.04 54.91 9.40
P/B 9.29 n/m 2.13
Price to free cash flow 39.79 n/m 25.18
EV/EBITDA 67.93 n/m 0.66
EV/Sales 7.67 60.33 9.02
Earnings yield 2.09% (11.19%) (32.88%)
Free cash flow yield 2.51% (3.16%) (23.13%)

Profitability

Metric CORT IBRX Biotechnology median
Gross margin 98.54% 99.34% 68.51%
Operating margin 11.51% (151.88%) 0.00%
Net margin 16.54% (598.56%) 0.00%
Free cash flow margin 20.20% (173.76%) 0.00%
Return on equity 21.74% 122.85% (51.96%)
Return on assets 17.16% (192.58%) (46.06%)
Return on invested capital 14.97% 0.00% 0.00%

Growth

Metric CORT IBRX Biotechnology median
Revenue growth (TTM) 30.02% 192.92% 6.76%
EPS growth (last fiscal year) (33.33%) 38.71% 29.88%
Revenue growth, 5-year CAGR 16.56% 184.76% 9.75%
Net income growth, 5-year CAGR (1.52%) 0.00% 0.00%

Health

Metric CORT IBRX Biotechnology median
Debt to equity 0.00 (0.74) 0.00
Current ratio 3.00 5.72 4.97
Net debt to EBITDA (8.83) (0.97) 1.01

Dividend

Metric CORT IBRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CORT IBRX Biotechnology median
Market cap 7.84b 8.49b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack